食管癌是侵袭性较高的消化道恶性肿瘤。尽管外科技术及多学科综合治疗不断发展，食管癌的预后及整体生存仍较差。近年来，新型分子靶向治疗的发展如火如荼。靶向药物以肿瘤相关的信号通路为靶点，阻断下游信号的传导，起到抑制肿瘤细胞生长和转移的作用。目前正式批准的食管癌靶向药物较少，以HER-2抑制剂为代表，主要用于HER-2阳性表达的转移性腺癌。新型制剂的研究尚不广泛，不深入。本文就转移性食管癌新型靶向治疗的研究进展进行综述。%Esophageal cancer is a highly aggressive malignant tumor of the digestive tract. Despite the continuous development of sur-gical techniques and multidisciplinary treatments, the prognosis and overall survival of esophageal cancer patients is still poor. In re-cent years, the development of new molecular targeted therapy has become well advanced. Drugs that target tumor-related signal pathways and block the transmission of downstream signals can inhibit the growth and metastasis of tumor cells. Currently, esopha-geal cancer-targeted drugs are rarely approved officially. HER-2 inhibitor represents these types of drugs because of its positive expres-sion of metastatic adenocarcinoma. However, studies on the preparation of new drugs are not extensive. In this paper, the research progress of a new targeted therapy for metastatic esophageal cancer is reviewed.
展开▼
